Novartis Venture Fund

Portfolio · 3

Averna Therapeutics

Genomic Medicines that Insert Therapeutic Genes into Safe Harbors Within the DNA

Led ★ 1 round $82.0M committed Latest: 2024-06

Fore Biotherapeutics

Precision Oncology Treatments

2 rounds $132.0M committed Latest: 2023-08

ImmPACT Bio

CAR-T Cell Therapies for Treating Cancer

2 rounds $111.0M committed Latest: 2022-01

Investment activity

1 portfolio exit on record.

Q&A

What is Novartis Venture Fund's primary investment focus?

Novartis Venture Fund primarily focuses on the Health Tech & Life Sciences sector, with all three of its portfolio companies and its single exit falling within this area.

Has Novartis Venture Fund had any recent exits?

Yes, ImmPACT Bio, a company in Novartis Venture Fund's portfolio, was acquired by Lyell Immunopharma in October 2024.

Which portfolio companies has Novartis Venture Fund invested in?

Novartis Venture Fund's portfolio includes Averna Therapeutics, which raised $82M.

What is the most recent investment stage for a Novartis Venture Fund portfolio company?

Fore Biotherapeutics, a portfolio company of Novartis Venture Fund, has reached a Series D funding stage, having raised $153.5M.

When was Novartis Venture Fund's most recent portfolio company added?

Novartis Venture Fund added a new portfolio company in June 2024.

What is the funding stage of Averna Therapeutics, a Novartis Venture Fund portfolio company?

Averna Therapeutics, a portfolio company of Novartis Venture Fund, is at the Series A funding stage and has raised $82M.